Revelation Financial Statements From 2010 to 2025

REVB Stock  USD 0.85  0.03  3.41%   
Revelation Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Revelation Biosciences' valuation are provided below:
Gross Profit
90.9 M
Market Capitalization
819.2 K
Earnings Share
(82.07)
We have found one hundred eighteen available trending fundamental ratios for Revelation Biosciences, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Revelation Biosciences recent market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. As of June 2, 2025, Market Cap is expected to decline to about 2.4 M. The current year's Enterprise Value is expected to grow to about (3.7 M)

Revelation Biosciences Total Revenue

0.0

Check Revelation Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Revelation Biosciences' main balance sheet or income statement drivers, such as Interest Expense of 42.2 K, Total Revenue of 0.0 or Other Operating Expenses of 5.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 6.0E-4. Revelation financial statements analysis is a perfect complement when working with Revelation Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Revelation Stock
Check out the analysis of Revelation Biosciences Correlation against competitors.
For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.

Revelation Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets6.3 M6.6 M1.1 B
Slightly volatile
Accounts Payable792.1 K783.6 K942.8 K
Very volatile
Cash6.2 M6.5 M73.3 M
Slightly volatile
Long Term Debt135.7 M200.3 M139.1 M
Slightly volatile
Net ReceivablesM8.8 M6.4 M
Slightly volatile
Good Will29.3 M30.8 M27 M
Slightly volatile
Short Term Investments7.8 B7.5 B2.3 B
Slightly volatile
Total Liabilities1.8 M1.9 MB
Slightly volatile
Long Term Investments192.4 M223.2 M172.6 M
Slightly volatile
Intangible Assets3.2 M2.6 MM
Slightly volatile
Total Current Liabilities1.8 M1.9 MB
Slightly volatile
Other Liabilities32.4 M58.3 M23.9 M
Slightly volatile
Other Current Assets63.4 K66.7 K3.9 M
Slightly volatile
Total Current Assets6.2 M6.6 M60 M
Slightly volatile
Common Stock49652232.1 M
Slightly volatile
Property Plant Equipment142.2 K149.7 K3.8 M
Pretty Stable
Short and Long Term Debt24.4 M27.4 M29.9 M
Slightly volatile
Short Term Debt2.5 M2.6 M17.8 M
Slightly volatile
Other Current Liabilities2.1 M1.4 M859.5 K
Slightly volatile
Non Current Assets Total53.5 K56.3 K4.6 M
Pretty Stable
Common Stock Shares Outstanding363.8 K346.5 K68.6 K
Slightly volatile
Liabilities And Stockholders Equity5.7 M6.6 M2.3 M
Slightly volatile
Cash And Short Term Investments6.5 M6.5 M5.1 M
Slightly volatile
Capital Stock496522747 K
Pretty Stable
Short and Long Term Debt Total13.4 K15.1 K16.4 K
Slightly volatile
Current Deferred Revenue2.3 M2.6 M2.9 M
Slightly volatile

Revelation Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses5.9 MM8.8 M
Slightly volatile
Total Operating Expenses12.9 MM15.3 M
Pretty Stable
Selling General Administrative4.2 M4.4 M18.2 M
Slightly volatile
Tax Provision11.2 M13.3 M9.3 M
Slightly volatile
Net Interest Income81.1 M106.8 M71.2 M
Slightly volatile
Interest Income105 M148.7 M93.5 M
Slightly volatile
Depreciation And Amortization36.1 K27.9 K115.8 K
Slightly volatile
Selling And Marketing Expenses21.4 K22.5 K106.6 K
Slightly volatile
Research Development4.4 M3.5 M1.5 M
Slightly volatile
Reconciled Depreciation26.1 K27.9 K19.1 K
Slightly volatile

Revelation Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation26.5 K27.9 K686.5 K
Slightly volatile
Total Cash From Financing Activities12.2 M12.8 M180 M
Slightly volatile
End Period Cash Flow6.2 M6.5 M48.4 M
Slightly volatile
Stock Based Compensation182.5 K168.8 K110.1 K
Slightly volatile
Begin Period Cash Flow15.6 M12 M53.5 M
Slightly volatile
Issuance Of Capital Stock7.8 M5.4 M8.4 M
Pretty Stable
Dividends Paid6.1 M6.9 M7.5 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables656.5 K1.1 M585.1 K
Slightly volatile
Capex To Depreciation0.650.68665.9811
Slightly volatile
Cash Per Share17.8218.756430
Slightly volatile
Income Quality1.161.21834.1488
Slightly volatile
Net Debt To EBITDA0.780.817821.4517
Slightly volatile
Current Ratio1.853.4313.2262
Slightly volatile
Capex Per Share0.05260.055310.5342
Slightly volatile
Interest Debt Per Share1.421.61.7479
Slightly volatile
Debt To Assets0.00660.00740.008
Slightly volatile
Ebt Per Ebit2.951.88571.7532
Pretty Stable
Effective Tax Rate0.00250.002729.5261
Slightly volatile
Quick Ratio1.853.4313.2262
Slightly volatile
Cash Ratio1.773.39613.1236
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0253
Slightly volatile
Debt Ratio0.00660.00740.008
Slightly volatile

Revelation Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.4 M2.6 M1.1 B
Slightly volatile

Revelation Fundamental Market Drivers

Forward Price Earnings0.8875
Cash And Short Term Investments6.5 M

Revelation Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
27th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Revelation Biosciences Financial Statements

Revelation Biosciences stakeholders use historical fundamental indicators, such as Revelation Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Revelation Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Revelation Biosciences' assets and liabilities are reflected in the revenues and expenses on Revelation Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Revelation Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.6 M2.3 M
Cost Of Revenue28.8 K18.5 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Revelation Biosciences is a strong investment it is important to analyze Revelation Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revelation Biosciences' future performance. For an informed investment choice regarding Revelation Stock, refer to the following important reports:
Check out the analysis of Revelation Biosciences Correlation against competitors.
For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. If investors know Revelation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revelation Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(82.07)
Return On Assets
(0.55)
Return On Equity
(2.33)
The market value of Revelation Biosciences is measured differently than its book value, which is the value of Revelation that is recorded on the company's balance sheet. Investors also form their own opinion of Revelation Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Revelation Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revelation Biosciences' market value can be influenced by many factors that don't directly affect Revelation Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revelation Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revelation Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revelation Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.